Brandon D. Becker - Bristol-Myers Squibb

基本信息

浏览量：19

职业迁徙

个人简介

Brandon D. Becker currently works as a Scientist of Patient Reported Outcomes at GlaxoSmithKline.

研究兴趣

论文共 41 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Improvements in Patient-Reported Outcomes after Treatment with Deucravacitinib in Patients with Psoriatic Arthritis: Results from a Randomized Phase 2 Trial

Vibeke Strand,Laure Gossec,Laura C. Coates,Alexis Ogdie,Jiyoon Choi,Brandon Becker,Joe Zhuo,Thomas Lehman,Miroslawa Nowak,Ayanbola Elegbe,Philip J. Mease,Atul Deodhar

ARTHRITIS CARE & RESEARCHno. 8 (2024): 1139-1148

引用0浏览0WOS引用

Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary

Kim A. Papp,Kenneth Gordon,Bruce Strober,Joe Zhuo,Brandon Becker,Yichen Zhong,Jennifer L. Beaumont,Tan P. Pham,Renata Kisa,Andrew A. Napoli,Subhashis Banerjee,April W. Armstrong

JAMA DERMATOLOGYno. 2 (2024): 204-209

引用0浏览0WOS引用

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

April W. Armstrong,Matthias Augustin,Jennifer L. Beaumont,Tan P. Pham,Stacie Hudgens,Kenneth B. Gordon,Joe Zhuo,Brandon Becker,Yichen Zhong,Renata M. Kisa,Subhashis Banerjee,Kim A. Papp

Dermatology and Therapypp.1-14, (2024)

引用0浏览0WOS引用

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch As Assessed by the Psoriasis Symptoms and Signs Diary

Andrew F. Alexis, Joseph F. Merola, Yue Zhong,Joe Zhuo,Brandon Becker,Andrew Napoli, Jeffrey S. Ross,Jennifer L. Beaumont,Michael DeRosa, Subhashis Banerjee,April W. Armstrong

Skinno. 2 (2024): s358-s358

引用0浏览0引用

Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy

Sang Hee Park,Yichen Zhong,Adam Sima,Vardhaman Patel,Joe Zhuo, Carla Roberts-Toler,Brandon Becker, Sara Hovland,Bruce Strober

SKIN The Journal of Cutaneous Medicineno. 2 (2023)

引用0浏览0引用

LP-187 Abstract Withdrawn

Marta Mosca,Laurent Arnaud,Anca Askanase,Coburn Hobar,Shalabh Singhal, Subhashis Banerjee,Shirley A. Pomponi, Joongdae Choi, Adrian Coles,Brandon Becker,Vibeke Strand

openalex（2023）

引用0浏览0引用

Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients with Moderate to Severe Psoriasis: Results fromthe Phase 3 POETYK PSO-1 and PSO-2 Trials

Matthias Augustin,Bruce Strober,April Armstrong,Jennifer Beaumont,Tan Pham,Stacie Hudgens,Joe Zhuo,Brandon Becker,Subhashis Banerjee,Renata Kisa,Kim Papp

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023): 112-112

引用0浏览0引用

Deucravacitinib in moderate to severe plaque psoriasis: Correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2

Diana Rubel,April W. Armstrong,Kim Papp,Joe Zhuo,Brandon Becker,Yichen Zhong,Jennifer Beaumont,Michael DeRosa,Renata M. Kisa,Subhashis Banerjee,Bruce Strober

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2023): 71-72

引用0浏览0引用

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Correlations Between Patient-Reported Outcomes and Clinical Responses in the Phase 3 Clinical Trials POETYK PSO-1 and POETYK PSO-2

April W Armstrong,Kim A Papp,Joe Zhuo,Brandon Becker,Yichen Zhong,Jennifer L Beaumont,Michael DeRosa,Renata M Kisa,Subhashis Banerjee,Bruce Strober

Skinno. 6 (2022): s63-s63

引用0浏览0引用

35205 Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials

Matthias Augustin,Bruce Strober,April W. Armstrong,Jennifer Beaumont,Tan P. Pham,Stacie Hudgens,Joe Zhuo,Brandon Becker,Subhashis Banerjee,Renata M. Kisa,Kim Papp

Journal of the American Academy of Dermatologyno. 3 (2022): AB156-AB156

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn